Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2013

Evotec, Dana-Farber Partner on Cancer Epigenetics Drug Development

  • Investigators at the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science and Evotec are working together to discover and commercialize cancer treatments based on epigenetic drug mechanisms, the organizations announced today.

    Together, Dana-Farber and Evotec hope to validate emerging epigenetic targets for oncology indications and demonstrate the drugability of the selected target families, they said. Financial terms of the agreement were not disclosed.

    “This pioneering partnership provides a unique opportunity to combine Evotec's drug discovery capabilities with Belfer Institute for Applied Cancer Science and Dana-Farber Cancer Institute's expertise in oncology disease biology to accelerate the development of new medicines for patients,” Jessie English, head of research at the Belfer Insitute, said in a statement.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »